SciSparc — raw details

Highlights

1 patentProfile claimed by owner

About

Cannabinoid Pharmaceuticals for Treatment of Central Nervous System Disorders

SciSparc is a specialty clinical-stage pharmaceutical company focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company is currently engaged in drug development programs based on THC and/or non-psychoactive cannabidiol (CBD), including SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimers disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.

Identity

Name	SciSparc
Slug	therapix-biosciences
Former names	Therapix Biosciences, Nasvax
Type / kind	startup
Crunchbase ID	therapix-biosciences
Source _id	agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNLVyoILDA

Status

Status	active
Status reason	Public on NASDAQ on Mar 2017;
Last update	2026-05-17

Location

HQ country code	IL
HQ region/district	Center District
HQ city	Giv'atayim
HQ address	Ariel Sharon 4, Giv'atayim, Israel

Web & social

Website	https://scisparc.com/
LinkedIn	https://www.linkedin.com/company/71540465
Twitter / X	https://twitter.com/SciSparc
Facebook	https://www.facebook.com/SciSparc

Classifications

Primary sector Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis

Technologies

Biologicals

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business models

B2B

Funding

Total raised	$63.8M
Current stage	Public
Market cap	$4.5M

Raw source document

Show full JSON (0 KB)

{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}